Recent Agreement with DM WDM and Quark Ventures Results in Successful Equity Transaction, Significant New Opportunities, and Future Open Market Support for New Client Pressure BioSciences

Aug 14, 2015, 09:00 ET from Quark Ventures

WROCLAW, Poland, Aug. 14, 2015 /PRNewswire/ -- Dom Maklerski WDM ("WDM"), Central and Eastern Europe's (CEE) leading small-cap investment bank, and Quark Ventures ("QV"), one of CEE's leading venture funds, today announced that key progress has been made as a result of a cooperation agreement recently signed between the financial services companies and their new client, Massachusetts (USA)-based Pressure BioSciences, Inc. (OTCQB: PBIO).  This progress includes:

  1. The sale of 1,000,000 shares of PBIO common stock to a European institutional investor on Tuesday, August 11th.  The shares of PBIO restricted stock were purchased at an approximate 78% premium to market by an investment company managed by one of the most recognized and respected portfolio and fund managers in Poland.  In lieu of cash, PBIO received 601,500 shares in the investment company, which is publicly-traded on the Main Market of the Warsaw Stock Exchange.  The investment company shares were valued at approximately $460,000 on the day of the transaction.  WDM acted as the lead financial advisor on this private placement transaction.
  2. Quark Ventures (a WDM affiliated company) and PBIO recently formed a joint venture in Poland, called Pressure BioSciences Europe Sp. z.o.o. ("PBIO Europe").  PBIO Europe intends to submit several multi-million dollar grant requests to a special, strategic economic-development investment portfolio of European Union ("EU") grant programs aimed at supporting innovative companies willing to develop and manufacture such products in Poland, and to subsequently commercialize them throughout Poland, the rest of the EU, and beyond. These programs are expected to deploy almost $100 Billion over the next five years.  With QV's guidance, PBIO has begun the process of preparing at least two grant applications for submission, based on the Company's powerful and unique Pressure Cycling Technology ("PCT") platform.
  3. In support of their business partner, QV has announced their intention to purchase up to $250,000 of PBIO common stock in the open market over the next six months.

 "As a leading micro and small cap investment bank in Poland, we are constantly looking for innovative, well-run, undervalued, high-potential micro-cap companies. We have already partnered with several companies in this category, introducing them to high-net-worth and institutional investors in Poland and the broader CEE area, as we help them finance their development and build long-term value. We are excited to now be working with PBIO, as we believe they offer great potential for success and high return-on-investment," said Wojciech Gudaszewski, Vice President of WDM.

Richard T. Schumacher, Chief Executive Officer of PBIO, stated, "The WDM Team is as impressive as it gets.  In a short period of time, they have guided us through a very successful securities transaction, introduced us to many financial and media leaders in Poland, helped us start the EU grant process, and offered to support PBIO in the US capital markets.  We believe this is the beginning of a long and rewarding relationship."

About Pressure BioSciences

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.      

About DM WDM

WDM is Central and Eastern Europe's leading small cap investment bank. It has been listed on the Warsaw Stock Exchange since 2007. Over the past 7 years, WDM has taken over 50 companies public on the Warsaw Stock Exchange. It has raised over $150,000,000 in private equity, venture capital and public financing for its clients. WDM provides access to CEE financing for North American clients.

About Quark Ventures

Quark Ventures is a leading Central and Eastern European venture fund with offices in Poland and the United States. Quark has a unique history of helping North American innovators accelerate growth by combining cost effective equity with European Union grants. Quark's passion is exponential innovation in life science, clean energy and new technology. Quark looks for the game changing and disruptive innovation that can grow rapidly into global enterprise.

SOURCE Quark Ventures